Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease.

This study supports a potential therapeutic use for MAO-A inhibitors in the treatment of depression and anxiety in patients with HD. PMID: 26825854 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26825854?dopt=Abstract

Source: Experimental Neurology - January 26, 2016 Category: Neurology Authors: Garcia-Miralles M, Ooi J, Bardile CF, Tan LJ, George M, Drum CL, Lin RY, Hayden MR, Pouladi MA Tags: Exp Neurol Source Type: research